Development of a rat model of oral small molecule receptor tyrosine kinase inhibitor-induced diarrhea

Involvement of Substance P in Peripheral Neuropathy Induced by Paclitaxel but Not Oxaliplatin

(2011) Y. Tatsushima et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

(2009) H. A. Burris et al.   CLINICAL CANCER RESEARCH

Effects of Food on the Relative Bioavailability of Lapatinib in Cancer Patients

(2009) Kevin M. Koch et al.   JOURNAL OF CLINICAL ONCOLOGY

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Decoding epithelial signals: critical role for the epidermal growth factor receptor in controlling intestinal transport function

(2008) D. F. McCole et al.   Acta Physiologica

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

(2008) John P. Crown et al.   BREAST CANCER RESEARCH AND TREATMENT

Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?

(2008) Richard M. Logan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

(2008) Q. Ryan et al.   ONCOLOGIST

Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

(2008) Yohann Loriot et al.   Nature clinical practice. Oncology